Clover Health Reports Fourth Quarter and Full Year 2024 Results; Provides Full Year 2025 Guidance investors.cloverhealth.com/news-releases/…

🍀Clover Update🍀 To enhance engagement and facilitate connections with the Company's investors, our CEO Andrew Toy is planning to answer questions from CLOV shareholders regarding Clover’s business, results, strategy, and future plans. Starting today, current shareholders can

Counterpart Health’s latest data report highlights how a relationship with a PCP that uses Counterpart Assistant is associated with better health outcomes in patients with congestive heart failure →  better clinical management, and fewer hospitalizations (18% lower) and

We reported strong 1Q25 earnings results today, and increased our full year 2025 Adjusted EBITDA and Adjusted Net Income guidance. Read more: investors.cloverhealth.com/static-files/a…

Leading up to Q1 2025 earnings, we asked Clover Health shareholders to submit questions for our CEO Andrew Toy, anything from strategy, to our business model, to how we think about the future, and our shareholders delivered. We’re honored you took the time to share such

Next up: Q2 2025. Our CEO Andrew Toy will answer a selection of questions from CLOV shareholders in the week following the conclusion of our upcoming Q2 2025 earnings conference call on August 5th. We encourage current shareholders to submit questions via the Q&A form on our

Today we announced a new community-based pharmacy program across New Jersey in partnership with IPC. The program is designed to help seniors better manage medications and stay healthier at home, supported by the local New Jersey pharmacies they know and trust. IPC’s iCare+™

Our latest data report highlights how a relationship with a PCP that uses Counterpart Assistant is correlated with greater identification of Chronic Obstructive Pulmonary Disease, more frequent specialty pulmonologist care, and significantly fewer hospitalizations (15% lower) and

Today’s 2Q25 earnings results reinforce our confidence in achieving our updated full year guidance for 2025 and highlight 32% year-over-year MA membership growth alongside continued positive adjusted Net Income and Adjusted EBITDA. Read more: investors.cloverhealth.com/static-files/d…

Thank you to our shareholders for your thoughtful Q&A participation this quarter. Your questions reflect genuine investment in our mission and strategic direction. We've published a focused collection of inquiries that illuminate our approach to advancing healthcare innovation

Yesterday we rang the Closing Bell Nasdaq Exchange! Our co-founder and Executive Chairperson Vivek Garipalli and Chief Executive Officer Andrew Toy rang the Closing Bell to celebrate our journey, achievements, and most importantly, the extraordinary team driving our mission to

Tomorrow at 10:15am EDT, our CEO Andrew Toy will deliver testimony before the House Committee on Energy and Commerce Subcommittee on Health on the transformative role of AI in healthcare. His testimony will showcase how our Clover Assistant platform is leading the way in AI by

This morning, our CEO Andrew Toy was honored to testify before the House Committee on Energy and Commerce Subcommittee on Health, highlighting how AI is already delivering advanced, data-driven healthcare to Americans, including seniors in rural and underserved communities.

Counterpart Assistant (CA) just got smarter with integrated AI-powered scribing. Unlike standalone tools, our solution makes it easier for clinicians to access data through a feature embedded directly into our value-based care platform, streamlining workflows and bringing

Announcing the rollout of Availity Essentials™ to increase efficiency across provider administrative functions while improving patient access to timely, quality care. Key enhancements: - Centralized Access - Streamlined Prior Authorization - Real-Time Transparency Just one of

A huge congratulations to Dr. Ian Duncan on his appointment as the 2025-2026 President-Elect and Vice-Chair of The Society of Actuaries! Clover has been privileged to benefit from Dr. Duncan's expertise and guidance as a member of our MA Board of Directors. His deep experience

Counterpart Assistant (CA) gets conversational. Our new generative AI capabilities help physicians prep faster, manage complexity and deliver high-quality value-based care. Physicians can now ask CA questions about a patient’s medical history in natural language and receive

Counterpart welcomes two new leaders to support growth and adoption of Counterpart Assistant for more partners, more clinicians, and more patients. New VP Blaine Lindsey will drive national enterprise growth while Gulf Region President Shannon Jacobs will scale operations in

Coming soon: Clover Health Q3 2025 earnings results are set for release on November 4, 2025. The week following earnings, our CEO Andrew Toy and CFO Peter Kuipers will continue the dialogue via our quarterly Q&A with CLOV shareholders. Please submit all inquiries via our

2026 Annual Enrollment Period is now open through 12/7 and we're pleased to offer high-choice PPO plans and HMO plans that deliver real results for seniors and physicians alike. More info: investors.cloverhealth.com/news-releases/…